Liu, Shiying
Bush, William S.
Miskimen, Kristy
Gonzalez-Vicente, Agustin
Bailey, Jessica N. Cooke
Konidari, Ioanna
McCauley, Jacob L.
Sedor, John R.
O’Toole, John F.
Crawford, Dana C.
Funding for this research was provided by:
National Institute of Diabetes and Digestive and Kidney Diseases (U54DK083912)
National Institutes of Health (U2CTR002818, R01 DK108329, R01 DK097836, UL1TR0002548)
Article History
Received: 21 February 2022
Revised: 15 July 2022
Accepted: 15 July 2022
First Online: 9 August 2022
Declarations
:
: This ancillary study was approved by the NEPTUNE Ancillary Study Committee and Steering Committee as well as local Institutional Review Boards. Written informed consent was obtained for adult participants. For pediatric patients, parents provided written consent and, when appropriate, assent was obtained.
: JRS has received research funding for randomized clinical trials in nephrotic syndrome from Goldfinch, Novartis, and Calliditas. He has also consulted for Maze, Goldfinch, Boehringer Ingelheim, in the last three years and receives royalties from Sanofi for transgenic mice. The other authors have no conflicts of interest to declare.